Laura Sepp-Lorenzino
Equibles does not estimate personal net worth.
Get an email with a short summary when Intellia Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NTLA alertsAbout Laura Sepp-Lorenzino
Laura Sepp-Lorenzino is recorded as Board Member at Lexeo Therapeutics, Inc. (LXEO) since January 1, 2026. The newest filing on record that lists Laura Sepp-Lorenzino as Board Member at Lexeo Therapeutics, Inc. (LXEO) is dated April 30, 2026. The proxy statement of Intellia Therapeutics, Inc. reports total compensation of $5,505,150 for Laura Sepp-Lorenzino in fiscal 2024, including a base salary of $512,000. Disclosed compensation is on record for 6 fiscal years. Intellia Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Lexeo Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Intellia Therapeutics, Inc. includes Edward J. Dulac III (CFO), Andrew D. Schiermeier (COO), James Basta (General Counsel) and 7 others.
Affiliation history
-
Current
2026-01-01–present
Last confirmed April 30, 2026
-
Intellia Therapeutics, Inc. (NTLA)
Source not stated
Current
Company network
Biotechnology · Healthcare
Board Member
2026-01-01–present
Leadership on record at Intellia Therapeutics, Inc.
- Edward J. Dulac III CFO
- Andrew D. Schiermeier COO
- James Basta General Counsel
- Michael P. Dube Chief Accounting Officer
- Bill Chase Board Member
- Brian Goff Board Member
- Georgia Keresty Board Member
- Georgia Keresty, Ph.D., M.P.H. Board Member
- John M. Leonard Board Member
- John M. Leonard, M.D. Board Member
Leadership on record at Lexeo Therapeutics, Inc.
- R. Nolan Townsend CEO, Board Member
- Kyle Rasbach CFO, Chief Accounting Officer
- Louis Tamayo CFO
- Jose Manuel Otero COO
- Jose Manuel Otero, Ph.D. COO
- Brenda Cooperstone Board Member
- Continuing Directors Board Member
- Dr. Laura Sepp-Lorenzino Board Member
- Mette Kirstine Agger Board Member
- Paula HJ Cholmondeley Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $512,000 | $5,505,150 |
| 2023 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $492,000 | $4,186,105 |
| 2022 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $470,000 | $3,716,128 |
| 2021 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $441,000 | $4,579,749 |
| 2020 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $420,000 | $1,690,526 |
| 2019 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Scientific Officer | $239,487 | $1,762,489 |
Recent activity
No call appearances or filed executive changes recorded yet.